Identification of a Specific Translational Machinery via TCTP-EF1A2 Interaction Regulating NF1-associated Tumor Growth by Affinity Purification and Data-independent Mass Spectrometry Acquisition (AP-DIA).


Journal

Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647

Informations de publication

Date de publication:
02 2019
Historique:
received: 06 08 2018
revised: 17 10 2018
pubmed: 2 11 2018
medline: 26 11 2019
entrez: 2 11 2018
Statut: ppublish

Résumé

Neurofibromatosis type 1 (NF1) is an autosomal dominant disease that predisposes individuals to developing benign neurofibromas and malignant peripheral nerve sheath tumors (MPNST). The mechanism of NF1-tumorigenesis or the curatives have not been established. Using unique trascriptome and proteome integration method, iPEACH (1), we previously identified translationally controlled tumor protein (TCTP) as a novel biological target for NF1-associated tumors (2). Here, we identified specific TCTP-interacting proteins by sequential affinity purification and data-independent mass spectrometry acquisition (AP-DIA/SWATH) to investigate the role of TCTP in NF1-associated malignant tumors. TCTP mainly interacts with proteins related to protein synthesis and especially to elongation factor complex components, including EF1A2, EF1B, EF1D, EF1G, and valyl-tRNA synthetase (VARS), in NF1-deficient malignant tumor cells. Interestingly, TCTP preferentially binds to EF1A2 (normally found only in neural and skeletal-muscle cells and several cancer cells), rather than EF1A1 despite the high homologies (98%) in their sequences. The docking simulation and further validations to study the interaction between TCTP and EF1A2 revealed that TCTP directly binds with EF1A2 via the contact areas of EF1A2 dimerization. Using unique and common sequences between EF1A2 and EF1A1 in AP-DIA/SWATH, we quantitatively validated the interaction of EF1A2 and TCTP/other elongation factors and found that TCTP coordinates the translational machinery of elongation factors via the association with EF1A2. These data suggest that TCTP activates EF1A2-dependent translation by mediating complex formation with other elongation factors. Inhibiting the TCTP-EF1A2 interaction with EF1A2 siRNAs or a TCTP inhibitor, artesunate, significantly down-regulated the factors related to protein translation and caused dramatic suppression of growth/translation in NF1-associated tumors. Our findings demonstrate that a specific protein translation machinery related to the TCTP-EF1A2 interaction is functionally implicated in the tumorigenesis and progression of NF1-associated tumors and could represent a therapeutic target.

Identifiants

pubmed: 30381327
pii: S1535-9476(20)31869-7
doi: 10.1074/mcp.RA118.001014
pmc: PMC6356078
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
EEF1A2 protein, human 0
NF1 protein, human 0
Neurofibromin 1 0
Peptide Elongation Factor 1 0
TPT1 protein, human 0
Tumor Protein, Translationally-Controlled 1 0

Banques de données

PDB
['4c0s', '1yz1']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

245-262

Informations de copyright

© 2019 Kobayashi et al.

Références

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13892-7
pubmed: 14623968
J Biol Chem. 2008 Apr 4;283(14):9399-413
pubmed: 18218617
Nucleic Acids Res. 2014 Nov 10;42(20):12939-48
pubmed: 25326326
EMBO J. 2002 Nov 15;21(22):6205-15
pubmed: 12426392
Genomics. 1987 Dec;1(4):353-7
pubmed: 2896629
Science. 1995 Aug 4;269(5224):688-90
pubmed: 7542803
Nat Methods. 2013 Dec;10(12):1246-53
pubmed: 24162925
Nat Methods. 2013 Dec;10(12):1239-45
pubmed: 24162924
J Proteome Res. 2016 Oct 7;15(10):3741-3751
pubmed: 27607350
Cell Death Differ. 2008 Aug;15(8):1211-20
pubmed: 18274553
Nat Genet. 2002 Jul;31(3):301-5
pubmed: 12053177
Nature. 2007 Feb 15;445(7129):785-8
pubmed: 17301792
FEBS Lett. 2015 May 8;589(11):1187-93
pubmed: 25862498
Nat Commun. 2015 Dec 22;6:10111
pubmed: 26694030
Mol Cell Proteomics. 2007 Sep;6(9):1638-55
pubmed: 17533153
Biochem Int. 1989 Aug;19(2):277-86
pubmed: 2479380
J Biol Chem. 2001 Dec 14;276(50):47542-9
pubmed: 11598139
Oncogene. 2008 Sep 18;27(42):5554-66
pubmed: 18504434
Breast Cancer Res Treat. 2007 Mar;102(1):31-41
pubmed: 16897428
Biochim Biophys Acta. 2006 May-Jun;1757(5-6):631-8
pubmed: 16806052
Mol Cell Biol. 2005 Apr;25(8):3117-26
pubmed: 15798198
Nat Protoc. 2013 Aug;8(8):1551-66
pubmed: 23868073
J Biol Chem. 2003 Jul 18;278(29):26958-69
pubmed: 12730209
Cancer Res. 2005 Apr 1;65(7):2755-60
pubmed: 15805275
Cancer Lett. 2007 Jan 8;245(1-2):303-14
pubmed: 16517066
ACS Chem Biol. 2016 Apr 15;11(4):882-8
pubmed: 26854499
Mol Cell Proteomics. 2013 May;12(5):1377-94
pubmed: 23358504
Cell Death Dis. 2012 Mar 01;3:e276
pubmed: 22378069
Nat Protoc. 2007;2(8):1896-906
pubmed: 17703201
Mol Cell Proteomics. 2009 Oct;8(10):2350-67
pubmed: 19525549
Cell. 1990 Jul 13;62(1):193-201
pubmed: 2114220
Trends Cell Biol. 2013 Jan;23(1):37-46
pubmed: 23122550
J Biol Chem. 2015 Apr 3;290(14):8694-710
pubmed: 25635048
Hepatology. 2012 Feb;55(2):491-505
pubmed: 21953552
Oncogene. 2006 Apr 27;25(18):2628-35
pubmed: 16369491
Nucleic Acids Res. 2017 Jan 4;45(D1):D1107-D1111
pubmed: 27899654
Proc Natl Acad Sci U S A. 1982 Oct;79(19):5876-80
pubmed: 6964392
Nature. 2002 Jan 31;415(6871):526-30
pubmed: 11793011
Nat Protoc. 2017 Feb;12(2):255-278
pubmed: 28079879
J Biol Chem. 2014 Sep 19;289(38):26314-26
pubmed: 25092287
Hepatology. 2008 Feb;47(2):511-20
pubmed: 18161050
J Biochem. 2006 Sep;140(3):393-9
pubmed: 16877446
BMC Cancer. 2005 Sep 12;5:113
pubmed: 16156888
J Biol Chem. 1998 Jun 26;273(26):16192-8
pubmed: 9632675
Nature. 2017 May 25;545(7655):505-509
pubmed: 28514442
J Cell Sci. 1999 Apr;112 ( Pt 8):1257-71
pubmed: 10085260

Auteurs

Daiki Kobayashi (D)

Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences.

Takaho Tokuda (T)

Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences.

Kyosuke Sato (K)

Department of Molecular Physiology, Faculty of Life Sciences.

Hiroki Okanishi (H)

Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences.

Megumi Nagayama (M)

Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences.

Mio Hirayama-Kurogi (M)

Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University.

Sumio Ohtsuki (S)

Department of Pharmaceutical Microbiology, Faculty of Life Sciences, Kumamoto University.

Norie Araki (N)

Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences,. Electronic address: nori@gpo.kumamoto-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH